Miguel Díaz-Canel, President of Cuba, today highlighted the approval of the Cuban Soberana Plus vaccine for use in the pediatric population over two years of age convalescing from COVID-19.
Through Twitter, the president stressed that this Tuesday the Center for State Control of Medicines, Equipment and Medical Devices (CECMED) authorized the emergency use of this drug.
“Our children and adolescents who suffered # COVID19 will be able to receive their dose of #SoberanaPlus. This Tuesday @cubacecmed announced the authorization of use for those over two years of age. #CubaVive,” Díaz-Canel tweeted.
The Cuban Minister of Foreign Relations, Bruno Rodríguez, expressed in the same social network about the news, that it constitutes a great joy for Cuban families; the health and protection of infants is a priority in Cuba, he added.
“Great rejoicing for Cuban families represents approval by @cubacecmed of Authorization for Emergency Use of the SoberanaPlus vaccine for pediatric population, from 2 years of age, convalescing from # COVID19. The health and protection of infants in #Cuba is a priority, “he wrote.
With the authorization of the emergency use of the Soberana Plus vaccine for the convalescent pediatric population of the disease, this age group will be able to receive the immunogen after two months or more from their hospital or home medical discharge.
According to CECMED, the approval is based on the partial results of a Phase I / II clinical trial with SoberanaPlus in children and adolescents recovered from COVID-19, which showed that the administration of a single dose is safe.
Likewise, the studies provided elements of benefit in immunological terms against the potential risk of reinfection by the SARS-CoV-2 virus, which causes the infectious disease.
